IN THE CLAIMS:

Claims 5, 7, 10, 12 through 15, 21, 22, and 24 are amended herein, claims 1, 2, 4, 8, and 9 are canceled, and new claims 28 through 35 are added. Claims 3, 16 through 20, and 23 were earlier canceled. All amendments are made without prejudice or disclaimer and applicants may pursue such claims in related applications. Please note that all claims currently pending and under consideration in the referenced application are shown below. This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1 through 4. (Canceled).

5. (Currently Amended) ~~The~~ A method ~~according to claim 4,~~ for delivering genetic material to a target cell *in vitro*, comprising:

preparing a gene delivery vehicle comprising an expressible nucleic acid molecule encoding a gene of interest, a virus including a capsid or envelope surrounding said expressible nucleic acid molecule, and a first member of a specific binding pair, said first member of the specific binding pair expressed by recombinant expression on an exterior of said capsid or envelope;

coupling a bispecific conjugate to said first member of the specific binding pair to form a gene delivery vehicle complex, said bispecific conjugate comprising a second member of the specific binding pair covalently coupled to a targeting moiety, said targeting moiety capable of binding to a target molecule associated with a surface of the target cell; and

delivering said gene delivery vehicle complex to the target cell *in vitro*, wherein said first member of the specific binding pair ~~is configured to have~~ comprises an immunoglobulin binding moiety having binding specificity to a constant region of an immunoglobulin.

6. (Original) The method according to claim 5, wherein said second member of the specific binding pair comprises an immunoglobulin.

7. (Currently Amended) The method according to claim ~~1~~ 5, wherein said capsid or envelope is incapable of binding to the target cell.

Claims 8 and 9. (Canceled).

10. (Currently Amended) ~~The~~ A kit of parts ~~according to claim 9~~ for delivering genetic material to a target cell, comprising:

a gene delivery vehicle comprising an expressible nucleic acid molecule encoding a gene of interest, a virus including a capsid or envelope surrounding said expressible nucleic acid molecule, and a first member of a specific binding pair;

said first member of the specific binding pair expressed by recombinant expression on an exterior of said capsid or envelope; and

a bispecific conjugate for coupling to said first member of the specific binding pair, said bispecific conjugate comprising a second member of the specific binding pair covalently coupled to a targeting moiety, said targeting moiety capable of binding to a target molecule associated with a surface of the target cell, wherein said first member of the specific binding pair comprises an immunoglobulin binding moiety that is capable of binding to a constant region of an immunoglobulin.

11. (Original) The kit of parts according to claim 10, wherein said immunoglobulin binding moiety comprises a moiety selected from the group consisting of protein A, protein G, and a Fc receptor.

12. (Currently Amended) The kit of parts according to claim ~~8~~ 10, wherein said second member of the specific binding pair comprises an immunoglobulin.

13. (Currently Amended) The kit of parts according to claim ~~8~~ 10, wherein said targeting moiety comprises an antibody or a fragment or a derivative thereof.

14. (Currently Amended) The kit of parts according to claim ~~8~~ 10, wherein said virus is derived from a virus selected from the group consisting of adenoviruses, adeno-associated viruses, and retroviruses by modification of the capsid or envelope of said virus by recombinant expression of the first member of the specific binding pair that inserts into the viral capsid or envelope.

15. (Currently Amended) The kit of parts according to claim ~~8~~ 10, wherein said target molecule is receptor for which said targeting moiety is a ligand.

Claims 16 through 20 (Canceled).

21. (Currently Amended) The kit of parts according to claim ~~8~~ 10, wherein said first member of the specific binding pair has no specific affinity for said target molecule associated with the surface of the target cell.

22. (Currently Amended) The kit of parts according to claim ~~8~~ 10, wherein said capsid or envelope is incapable of binding to the target cell.

23. (Canceled).

24. (Currently Amended) The kit of parts according to claim ~~8~~ 10, comprising a multitude of different bispecific conjugates, comprising the same second member of the specific binding pair but a number of different targeting moieties.

25. (New) The method of claim 5, wherein said immunoglobulin binding moiety comprises a moiety selected from the group consisting of protein A, protein G, and a Fc receptor.

26. (New) The method of claim 5, wherein said first member of the specific binding pair has no specific affinity for said target molecule associated with the surface of the target cell.

27. (New) The method of claim 5, wherein said virus is derived from a virus selected from the group consisting of adenoviruses, adeno-associated viruses, and retroviruses by modification of the capsid or envelope of said virus by recombinant expression of the first member of the specific binding pair that inserts into the viral capsid or envelope.

28. (New) A targeted gene delivery vehicle complex, said targeting gene delivery vehicle complex comprising:

a gene delivery vehicle coupled with a bispecific conjugate, said gene delivery vehicle comprising:

an expressible nucleic acid molecule encoding a gene of interest, a virus including a capsid or envelope surrounding said expressible nucleic acid molecule, and a first member of a specific binding pair,

said first member of the specific binding pair being recombinantly expressed on an exterior of said capsid or envelope; and wherein said first member of the specific binding pair comprises an immunoglobulin binding moiety that is capable of binding to a constant region of an immunoglobulin;

wherein said bispecific conjugate comprises a second member of said specific binding pair covalently coupled to a targeting moiety capable of binding to a target molecule associated with the surface of said target cell.

29. (New) The targeted gene delivery vehicle complex of claim 28, wherein said second member of the specific binding pair comprises an immunoglobulin.

30. (New) The targeted gene delivery vehicle complex of claim 28, wherein said immunoglobulin binding moiety comprises a moiety selected from the group consisting of protein A, protein G, and a Fc receptor.

31. (New) The targeted gene delivery vehicle complex of claim 28, wherein said virus is derived from a virus selected from the group consisting of adenoviruses, adeno-associated viruses, and retroviruses by modification of the capsid or envelope of said virus by recombinant

expression of the first member of the specific binding pair that inserts into the viral capsid or envelope.

32. (New) The targeted gene delivery vehicle complex of claim 28, wherein said targeting moiety comprises an antibody or a fragment or a derivative thereof.

33. (New) A gene delivery vehicle comprising:
an expressible nucleic acid molecule encoding a gene of interest,
a virus including a capsid or envelope surrounding said expressible nucleic acid molecule, and
a first member of a specific binding pair,

said first member of the specific binding pair being recombinantly expressed on an exterior of said capsid or envelope, and said first member of the specific binding pair comprising an immunoglobulin binding moiety that is capable of binding to a constant region of an immunoglobulin.

34. (New) The gene delivery vehicle according to claim 33, wherein said immunoglobulin binding moiety comprises a moiety selected from the group consisting of protein A, protein G, and a Fc receptor.

35. (New) The gene delivery vehicle according to claim 33, wherein said virus is derived from a virus selected from the group consisting of adenoviruses, adeno-associated viruses, and retroviruses by modification of the capsid or envelope of said virus by recombinant expression of the first member of the specific binding pair that inserts into the viral capsid or envelope.